Ardelyx, Inc. Common Stock ARDX
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T02:20:14.817Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T22:35:04.723178678Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-12T02:20:14.481359+00:00
Ardelyx, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 2.28 | 745.0% | 54.9% | |||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | 3.01 | 65.8% | 5.8% | |||
| 40Δ | 3.24 | 77.4% | 8.4% | 3.07 | 67.4% | 5.3% |
| 45Δ | 3.19 | 79.0% | 7.4% | 3.12 | 69.0% | 4.8% |
| 50Δ | 3.14 | 80.6% | 6.4% | 3.17 | 70.6% | 4.3% |
| 55Δ | 3.09 | 82.2% | 5.4% | |||
| 60Δ | 3.04 | 83.8% | 4.4% | |||
| 65Δ | 2.97 | 85.4% | 3.5% | |||
| 70Δ | 2.89 | 86.9% | 3.0% | |||
| 75Δ | 2.81 | 88.4% | 2.5% | |||
| 80Δ | 2.73 | 90.0% | 2.0% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.28
- IV
- 745.0%
- B/E move
- 54.9%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.01
- IV
- 65.8%
- B/E move
- 5.8%
40Δ
- Pseudo strike
- 3.24
- IV
- 77.4%
- B/E move
- 8.4%
- Pseudo strike
- 3.07
- IV
- 67.4%
- B/E move
- 5.3%
45Δ
- Pseudo strike
- 3.19
- IV
- 79.0%
- B/E move
- 7.4%
- Pseudo strike
- 3.12
- IV
- 69.0%
- B/E move
- 4.8%
50Δ
- Pseudo strike
- 3.14
- IV
- 80.6%
- B/E move
- 6.4%
- Pseudo strike
- 3.17
- IV
- 70.6%
- B/E move
- 4.3%
55Δ
- Pseudo strike
- 3.09
- IV
- 82.2%
- B/E move
- 5.4%
- Pseudo strike
- IV
- B/E move
60Δ
- Pseudo strike
- 3.04
- IV
- 83.8%
- B/E move
- 4.4%
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- 2.97
- IV
- 85.4%
- B/E move
- 3.5%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 2.89
- IV
- 86.9%
- B/E move
- 3.0%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 2.81
- IV
- 88.4%
- B/E move
- 2.5%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 2.73
- IV
- 90.0%
- B/E move
- 2.0%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 193.38% | |
| 118.07% | |
| 86.88% | |
| 218.16% | |
| 162.84% | |
| 234.19% | |
| 150.91% | |
| 201.54% | |
| 187.98% | |
| 210.17% | |
| 162.65% | |
| 203.88% | |
| 161.03% | |
| 187.45% | |
| 230.83% | |
| 165.47% | |
| 222.23% |
Biotechnology
ARGX
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The…
More →ARMP
Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of specific bacteriophage therapies for the treatment of antibiotic-resistant…
More →ARQT
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company is headquartered in…
More →ARTV
Artiva Biotherapeutics, Inc. is a cutting-edge biotechnology firm dedicated to revolutionizing cancer therapy through its proprietary natural killer (NK) cell platform. With a…
More →ARVN
Arvinas, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development, and commercialization of therapies to break down disease-causing proteins.…
More →ARWR
Description unavailable
More →